title: [Continuous subcutaneous infusion of peplomycin in oral squamous carcinoma].
abstract: To determine the effect of continuous subcutaneous infusion of peplomycin on both antitumor activity and pulmonary toxicity, thirty-two patients with previously untreated oral squamous carcinoma were given peplomycin via osmotic microinfusion pump (SP-5, Nipro Co., Ltd.) at a daily dose of 5.0 mg subcutaneously. The mean dosage of peplomycin given was 79.8 mg. An overall response rate of 62.5% was achieved, with 21.9% complete response, and 40.6% partial response. The maximum reduction of tumor volume for responder could be generally observed when peplomycin was given at about 60 mg continuously. The most frequently encountered toxicity was a mucocutaneous reaction, manifested by stomatitis (34.4%) and skin eruption (18.8%), but they were mild and tolerable. A local skin reaction also occurred at the site of drug injection, and an ulcer formation developed in 12.5% of patients. Monitoring of pulmonary function by means of PaO2 revealed that 32.0% of patients had a decrease over 10% after peplomycin administration. However, interstitial pneumonitis eventually occurred in only one patient (3.1%). In conclusion, the regimen of continuous infusion of peplomycin is a useful method to administer peplomycin safely without reducing the antitumor effect compared to conventional intermittent injection.
authors: Dept. of Oral Surgery, School of Medicine, Chiba University.
authors: H
authors: H
authors: Kanazawa
authors: K
authors: K
authors: Takahashi
authors: Y
authors: Y
authors: Hanazawa
authors: S
authors: S
authors: Uchiyama
authors: T
authors: T
authors: Takahara
authors: M
authors: M
authors: Takahara
authors: M
authors: M
authors: Muto
authors: M
authors: M
authors: Kinehara
authors: K
authors: K
authors: Sato
mesh_terms: D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007263:Infusions, Parenteral / Q000379:methods; D008168:Lung / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000097:blood / Q000188:drug therapy*; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D017663:Peplomycin; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012074:Remission Induction; D012867:Skin; D012883:Skin Ulcer / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced
chemical_list: D001761:Bleomycin; D017663:Peplomycin; D010100:Oxygen